Literature DB >> 26574632

Noninvasive Papillary Basal-like Urothelial Carcinoma: A Subgroup of Urothelial Carcinomas With Immunohistochemical Features of Basal Urothelial Cells Associated With a High Rate of Recurrence and Progression.

Kien T Mai1, Christopher G Ball, Eric C Belanger.   

Abstract

BACKGROUND: We investigated the clinical and pathologic significance of a subgroup of noninvasive papillary urothelial carcinomas (UCs) expressing reactivity to urothelial basal cell markers.
DESIGN: In total, 302 consecutive cases of noninvasive papillary UC were evaluated immunohistochemically with cytokeratin 5 (CK5)/CD44. Any UC that was reactive for greater than 25% thickness of the urothelium was designated as basal-like urothelial carcinoma (BUC); remaining UC cases were designated as non-BUC. The follow-up period was up to 3 years. Historical review of UC was extended for up to 3 retrospective years.
RESULTS: Among 302 noninvasive UC, BUC was identified in 33 of 256 (12.9%) low-grade UC and 8 of 46 (17%) high-grade UC (P=0.041). Immunoreactivity for CD44 was similar to that of CK5, but displayed weaker and more diffuse staining. CK20 was reactive in 9 cases, primarily high-grade BUC. Other basal cell markers (34bE12, p63, bcl2, and EP4) were found to be neither sensitive nor specific in detecting UC with high CK5 expression. In comparison with non-BUC, BUC was associated with increased multifocality, larger tumor size, higher recurrence rate, and more frequent upgrading and stage progression. In the follow-up period of 3 years, distant metastasis occurred in 6 cases of which 5 were in the BUC subgroup.
CONCLUSIONS: Our results showed that noninvasive papillary BUC represents a small subset associated with increased risk of tumor recurrence and progression. The aggressive behavior is likely associated with basal-like features of BUC, as seen in carcinomas with basal cell features in other body sites.

Entities:  

Mesh:

Year:  2016        PMID: 26574632     DOI: 10.1097/PAI.0000000000000224

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  3 in total

1.  Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis.

Authors:  Danijel Sikic; Bastian Keck; Sven Wach; Helge Taubert; Bernd Wullich; Peter J Goebell; Andreas Kahlmeyer; Peter Olbert; Philipp Isfort; Wilhelm Nimphius; Arndt Hartmann; Johannes Giedl
Journal:  PLoS One       Date:  2017-06-20       Impact factor: 3.240

2.  Cytokeratin 5 and cytokeratin 6 expressions are unconnected in normal and cancerous tissues and have separate diagnostic implications.

Authors:  Cosima Völkel; Noémi De Wispelaere; Sören Weidemann; Natalia Gorbokon; Maximilian Lennartz; Andreas M Luebke; Claudia Hube-Magg; Martina Kluth; Christoph Fraune; Katharina Möller; Christian Bernreuther; Patrick Lebok; Till S Clauditz; Frank Jacobsen; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Stefan Steurer; Sarah Minner; Rainer H Krech; David Dum; Till Krech; Andreas H Marx; Ronald Simon; Eike Burandt; Anne Menz
Journal:  Virchows Arch       Date:  2021-09-24       Impact factor: 4.064

Review 3.  Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression.

Authors:  Francesca Sanguedolce; Magda Zanelli; Andrea Palicelli; Stefano Ascani; Maurizio Zizzo; Giorgia Cocco; Lars Björnebo; Anna Lantz; Ugo Giovanni Falagario; Luigi Cormio; Giuseppe Carrieri
Journal:  Int J Mol Sci       Date:  2022-07-15       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.